Messages about big pharma

David R. Hamilton PhD

From 2002 to 2006, the number of drugs that were axed after Phase-II clinical trials (volunteer trials) increased by 20% because the drugs couldn’t beat the placebos they were compared against. More recently, in 2008, a new gene therapy for Parkinson’s disease failed against the placebo. Similarly, in March 2009, Eli Lilly withdrew a new drug for schizophrenia because the placebo effect was double that expected. Also in March 2009, Osiris Therapeutics’ new drug for Crohn’s disease was also withdrawn due to a high placebo effect.